Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange.
Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market